The central nervous system (CNS) has a reduced capacity to regenerate, and neuronal loss is often irreversible and can cause functional impairments (Gurgo et al., 2002;Li and Chen, 2016). Specific areas of brain control different nervous functions (Gudiene and Burba, 2003). Chronic diseases represent more than 60% of deaths in the world. Lifestyle, environmental factors and genetic predisposition can increase their incidence (Alesci, Miller et al., 2021). Neurodegenerative disorders are characterized by the progressive loss of neuron populations and can be classified according to their clinical presentation: with extrapyramidal and pyramidal symptoms, and with cognitive or behavioural disorders (Dugger and Dickson, 2017). They afflict a high percentage of the world's population, with predominance of dementia, Huntington's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD) (Gitler et al., 2017). The estimates about these syndromes showed that they are the second cause of death in 2016 (Feigin and Vos, 2019), and lots of studies confirm that the number of people affected by dementia will increase, and by 2040, there will be 81.1 million people affected by this pathology (Ferri et al., 2005). These pathologies are chronic (Walker, 2018), and there is not yet a definitive cure. Some treatments aiming to slow down the progression of the neurodegenerative diseases, relieve the pain of the patient, improve symptoms and extend sufferer autonomy and functionality (Moosmann and Behl, 2002). Among the cures evaluated to treat these disorders, there is neuronal regeneration. Regenerative therapies, which are mainly based on the principle of neuroplasticity, use stem cell transplantation to produce new neurons (Li and Chen, 2016). However, this therapy fails to generate large quantities of neurons; furthermore, some factors,